CD248 and neoplasm: There was no significant difference between the Mock and E3K CAR-T cell treated cohorts in terms of primary tumor growth or weight at necropsy (figure 3D), however, E3K CAR-T cell treated mice showed a significant ablation of endosialin+ cells in the primary tumor (figure 3E) and a significant reduction in overall metastatic burden and number of metastatic lesions (figure 3F).